If you have Osteogenesis Imperfecta (brittle bone disease) and you are aged 18 years or over you may be eligible to take part in the TOPaZ trial. The trial is being carried out across the UK, Ireland, France, the Netherlands and Denmark and aims to determine if a two year spell of treatment with a drug called Teriparatide (TPTD) following by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with Osteogenesis Imperfecta. If you are interested in reading more about this study download the current patient information leaflet here. Document TOPaZ Leaflet (219.34 KB / PDF) Even if you are not attending one of the participating centre, it is still possible for you to take part in the trial by contacting the co-ordinating centre by telephone, post or email. TOPaZ Trial Office Edinburgh Clinical Trials Unit University of Edinburgh Contact details Work: +44 (0) 131 651 9915 Email: topaz.trial@ed.ac.uk This article was published on 2024-09-24
